EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
Johanna Latzka(Universitätsklinikum St. Pölten), Franz Trautinger, Nicola Pimpinelli(University of Florence), Chalid Assaf(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Robert Knobler(Medical University of Vienna), Jan P. Nicolay(German Cancer Research Center), Pablo L. Ortiz‐Romero(Research Institute Hospital 12 de Octubre), Ulrike Wehkamp(European Organisation for Research and Treatment of Cancer), Emmilia Hodak(Rabin Medical Center), Pietro Quaglino(Department of Medical Sciences), Evangelia Papadavid(National and Kapodistrian University of Athens), M. Bagot, Rein Willemze(Leiden University), Annamari Ranki(University of Helsinki), Emmanuella Guenova(University of Tübingen), Julia Scarisbrick(University Hospitals Birmingham NHS Foundation Trust), Maarten H. Vermeer(Leiden University Medical Center), Liisa Väkevä(Helsinki University Hospital), Constanze Jonak, Reinhard Dummer(University Hospital of Zurich), Sean Whittaker(Norfolk and Norwich University Hospitals NHS Foundation Trust), Stephen Morrris(Guy's Hospital), Antonio Cozzio(Kantonsspital St. Gallen), Rudolf Stadler(Johannes Wesling Klinikum Minden), Claus‐Detlev Klemke(Städtisches Klinikum Karlsruhe), Robert Gniadecki(University of Copenhagen)
Cited by 164
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k